Search
Now showing items 1-10 of 51
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
(2020-02-24)
AIMS: To examine the association between socioeconomic status (SES) and disease-modifying therapy (DMT) prescribing patterns in people with relapsing-remitting multiple sclerosis (pwRRMS). METHODS: A cross-sectional analysis ...
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
(Elsevier, 2020-10-23)
Background
There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance ...
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908